Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam

May 24, 2012 updated by: UCB Pharma

Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam (Keppra®) (SOLUCION Study)

Phase IV, observational, post-authorization, cross sectional, open-label, multicenter study to evaluate the acceptability of oral solution of levetiracetam in patients with partial epilepsy as assessed by a questionnaire.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

600

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Alcala De Henares, Spain
      • Alcazar De San Juan, Spain
      • Alcorcon, Spain
      • Alicante, Spain
      • Alzira Valencia, Spain
      • Avila, Spain
      • Badajoz, Spain
      • Barcelona, Spain
      • Benidorm, Spain
      • Caceres, Spain
      • Cadz, Spain
      • Castellon, Spain
      • Coruna, Spain
      • Cuenca, Spain
      • Elda, Spain
      • Eliana, Spain
      • Girona, Spain
      • Granada, Spain
      • Guadalajara, Spain
      • Hospitalet Del Llobregat, Spain
      • Langreo, Spain
      • Las Palmas, Spain
      • Leon, Spain
      • Lleida, Spain
      • Lorca Murcia, Spain
      • Lugo, Spain
      • Madrid, Spain
      • Malaga, Spain
      • Manzanares, Spain
      • Manzanares Ciudad Real, Spain
      • Mataro, Spain
      • Merida Badajoz, Spain
      • Mostoles, Spain
      • Murcia, Spain
      • Oviedo, Spain
      • Palencia, Spain
      • Palmar, Spain
      • Palmas de Gran Canaria, Spain
      • Pamplona, Spain
      • Pontevedra, Spain
      • Puerto Del Rosario, Spain
      • Roca Del Valles, Spain
      • Sabadell, Spain
      • Salamanca, Spain
      • San Fernando, Spain
      • Santa Cruz De Tenerife, Spain
      • Sevilla, Spain
      • Terrassa, Spain
      • Teruel, Spain
      • Toledo, Spain
      • Valencia, Spain
      • Vigo Pontevedra, Spain
      • Zamora, Spain
      • Zaragoza, Spain

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Study populaton is defined. See Eligibility Criteria.

Description

Inclusion Criteria:

  • Patients 16 years old or older diagnosed with partial epilepsy with or without generalization receiving levetiracetam oral solution for at least 28 days before the study

Exclusion Criteria:

  • Patients with disturbances of the sense of taste and smell that can interfere with the assessment of the parameters of the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Time Perspectives: Retrospective

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

UCB Pharma

Investigators

  • Study Director: Helena Marin Muñoz, MD, UCB Pharma

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2006

Primary Completion (Actual)

July 1, 2006

Study Completion (Actual)

July 1, 2006

Study Registration Dates

First Submitted

April 28, 2006

First Submitted That Met QC Criteria

April 28, 2006

First Posted (Estimate)

April 27, 2006

Study Record Updates

Last Update Posted (Estimate)

May 25, 2012

Last Update Submitted That Met QC Criteria

May 24, 2012

Last Verified

May 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • N01242

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Epilepsy

Clinical Trials on Levetiracetam

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe